

Technology Advisory Committee A Interests Register

**Topic: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
[ID1676]**

Publication Date: 17 November 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Abdallah Al-Mohammad	TA Committee Member	Direct - financial	<p>Attended advisory boards regarding PARAGON-HF with Novartis in October 2019 and IV iron in heart failure with Pharmacosmos January 2021,</p> <p>Received honoraria for talks from AstraZeneca July 2020, Janssen October 2020 and Takeda January 2021</p> <p>His department received a small grant from AstraZeneca in December 2020 for purchase of blood pressure machines for HF patients to allow uptitration of drugs remotely.</p>		06/09/2021		It was agreed that this declaration would not prevent them participating in the meeting.
Professor Somnath Mukherjee	Clinical Expert	Indirect – non-financial	Co-investigator, LUD2015-005 trial (a phase I trial evaluating durvalumab in combination with chemotherapy and	N/A	29/01/2021	N/A	It was agreed that this declaration would not prevent them providing expert advice to the committee.

			chemoradiotherapy in metastatic and operable oesophageal cancer) and is also is a member of, Oesophago-gastric subgroup of NCRI Clinical Studies group (ie representing Upper GI CSG of NCRI).				
Professor Anne Thomas	Clinical Expert	None		N/A	29/01/2021	N/A	
Mr David Chuter	Patient Expert	None		N/A	18/08/2021	N/A	

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.